secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-05-24T23:59:59+00:00
Accession:  0001787306-23-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis CCO Ken Lock resigns; Ayisha Jeter named interim CCO
------------------------------------------------------------

- Ken Lock, SVP and CCO since Oct 2019, resigns effective June 2, 2023 to attend to personal matters.
- Ayisha Jeter, VP of Market Access since June 2020, appointed interim CCO.
- Company has commenced search for a permanent chief commercial officer.
- Lock led commercialization of ZORYVE (roflumilast) cream 0.3% for plaque psoriasis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/0001787306-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000048/arqt-20230522.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer